Free Trial
→ A new rule goes live in July — and the banks are quietly cashing in (From American Alternative) (Ad)
NASDAQ:MURA

Mural Oncology 3/11/2025 Earnings Report

Mural Oncology logo
$2.46 -0.01 (-0.40%)
As of 12:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Mural Oncology EPS Results

Actual EPS
-$2.01
Consensus EPS
-$1.96
Beat/Miss
Missed by -$0.05
One Year Ago EPS
-$3.57

Mural Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mural Oncology Announcement Details

Quarter
Date
3/11/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Mural Oncology's next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules.

Conference Call Resources

Mural Oncology Earnings Headlines

Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc
June 16, 2025 | markets.businessinsider.com
BlackRock discloses 1.64% stake in Mural Oncology
June 13, 2025 | investing.com
A new rule goes live in July — and the banks are quietly cashing in
A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.
June 20, 2025 | American Alternative (Ad)
Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc
June 13, 2025 | markets.businessinsider.com
BlackRock discloses 1.39% stake in Mural Oncology
June 12, 2025 | investing.com
BlackRock Reveals 1.58% Holding in Mural Oncology
June 5, 2025 | msn.com
See More Mural Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mural Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mural Oncology and other key companies, straight to your email.

About Mural Oncology

Mural Oncology (NASDAQ:MURA), a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

View Mural Oncology Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles